Research programme: alcoholism therapy - Tonix PharmaceuticalsAlternative Names: TNX-301
Latest Information Update: 30 May 2012
At a glance
- Originator Tonix Pharmaceuticals Inc
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase Unknown Alcoholism
Most Recent Events
- 30 May 2012 Investigation in Alcoholism in USA (unspecified route)